Abstract 187P
Background
Chemoradiation in Stomach is indicated in patients who do not receive perioperative chemotherapy. While contouring the organs at risk in CRT of stomach spleen is not considered as the organ at risk (OARS). Leukopenia is also seen very commonly during the CRT of stomach. We are trying to correlate the grade of leukopenia to the dose received by spleen during CRT of stomach. The primary aim of this study -To determine the dose achieved by Spleen during the Post Operative Adjuvant Radiotherapy of Carcinoma Stomach. Correlate the dose achieved to the weekly blood counts (Grade 3 Hematological Toxicity).
Methods
Patients attending Kasturba Medical College OPD diagnosed with Carcinoma Stomach and planned for Adjuvant Chemoradiation were considered for the study. We analyzed 42 patients from the Jan 2018 to December 2018. The Dosimetric and Volumetric Parameters were calculated for Spleen. The patients in our study underwent Upfront Gastrectomy (Total/Partial) and received 2 cycles of Adjuvant Chemotherapy (CAPOX). Then referred for adjuvant Chemoradiation.
Results
The Mean dose achieved was 36 Gy. The range of dose received by the spleen ranged from 35Gy- 45 Gy. The doses were high when splenic nodes were irradiated. 18 patients (42%) presented with Grade 3 Hematological toxicity( Leukopenia). 15 patients (35%) could not receive Concurrent Chemotherapy in view of non recovery of Hematological Toxicities.
Conclusions
From our study we found that Spleen is a Dose limiting Structure while planning the Adjuvant Post Operative Radiotherapy in Carcinoma Stomach. The dose received by spleen can be correlated with the grade of Leukopenia in patients receiving adjuvant CRT for Carcinoma Stomach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr Umesh Velu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
448P - Incidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy
Presenter: Alekhya Mandepudi
Session: Poster display session
Resources:
Abstract
449P - Utility of screening tool for assessment of chemotherapy induced peripheral neuropathy in cancer patients
Presenter: PRUTHVI Paibhavi
Session: Poster display session
Resources:
Abstract
450P - Supportive care to control nausea and dizziness in malignant tumours: A systematic review
Presenter: Rainer Spiegel
Session: Poster display session
Resources:
Abstract
451P - The safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancers: A retrospective study
Presenter: Nobuhiro Hattori
Session: Poster display session
Resources:
Abstract
452P - Expression of erythropoietin receptor in patient with anemia related chemotherapy and its correlation with absolute reticulocyte count
Presenter: Irza Wahid
Session: Poster display session
Resources:
Abstract
453P - Body mass index did not correlate with short term overall survival in breast cancers
Presenter: Jungsun Lee
Session: Poster display session
Resources:
Abstract
454P - Predictors of severity and comparison of CTCAE V3.0 vs V4.3 in assessing chemotherapy induced extravasation injuries
Presenter: Sangana Reddy
Session: Poster display session
Resources:
Abstract
455P - Assessment of nutritional status and quality of life among cancer patients undergoing chemotherapy
Presenter: Sri Prathima
Session: Poster display session
Resources:
Abstract
456P - Use of gamma irradiated bone allografts in treatment of various bone tumours
Presenter: Anchal Mishra
Session: Poster display session
Resources:
Abstract
457P - The prevalence of vitamin D deficiency in Thai cancer patients, its dynamics and association with cancer survival
Presenter: Chavapon Ngokngarm
Session: Poster display session
Resources:
Abstract